Literature DB >> 19019309

Therapeutic options in other metabolic myopathies.

Matthias Vorgerd1.   

Abstract

Adult patients with metabolic myopathies typically present with exercise-induced pain, cramps, fatigue, and myoglobinuria. The current therapeutic options of glycogen and lipid storage myopathies include dietary treatments, excersise training, and pharmacological supplementations. Herein is a review of evidence from randomized controlled trials in McArdle disease (glycogen storage disease type V, muscle phosphorylase deficiency) and carnitine palmitoyltransferase (CPT) 2 deficiency. A brief overview on current treatment options in rhabdomyolysis is also included because patients with McArdle disease and CPT 2 often experience such potentially life-threatening complications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19019309      PMCID: PMC4514707          DOI: 10.1016/j.nurt.2008.08.006

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  21 in total

Review 1.  Creatine for treating muscle disorders.

Authors:  R A Kley; M Vorgerd; M A Tarnopolsky
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  144th ENMC International Workshop: Outcome Measures in McArdle Disease, 29 September-1 November 2006, Naarden, The Netherlands.

Authors:  R Quinlivan; J Vissing
Journal:  Neuromuscul Disord       Date:  2007-05-08       Impact factor: 4.296

3.  Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study.

Authors:  Matthias Vorgerd; Jochen Zange; Rudolf Kley; T Grehl; Anika Hüsing; Matthias Jäger; Klaus Müller; Rolf Schröder; Wilhelm Mortier; Klaus Fabian; Jean-Pierre Malin; Alwin Luttmann
Journal:  Arch Neurol       Date:  2002-01

4.  Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose.

Authors:  Mette C Ørngreen; David B Olsen; John Vissing
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

5.  Aerobic conditioning: an effective therapy in McArdle's disease.

Authors:  Ronald G Haller; Phil Wyrick; Tanja Taivassalo; John Vissing
Journal:  Ann Neurol       Date:  2006-06       Impact factor: 10.422

Review 6.  Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).

Authors:  R Quinlivan; R J Beynon; A Martinuzzi
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

7.  Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity.

Authors:  S T Andersen; J Vissing
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-12       Impact factor: 10.154

Review 8.  Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects.

Authors:  Jean-Paul Bonnefont; Fatima Djouadi; Carina Prip-Buus; Stephanie Gobin; Arnold Munnich; Jean Bastin
Journal:  Mol Aspects Med       Date:  2004 Oct-Dec

9.  Genotype modulators of clinical severity in McArdle disease.

Authors:  Juan C Rubio; Félix Gómez-Gallego; Catalina Santiago; Inés García-Consuegra; Margarita Pérez; María I Barriopedro; Antoni L Andreu; Miguel A Martín; Joaquín Arenas; Alejandro Lucia
Journal:  Neurosci Lett       Date:  2007-06-21       Impact factor: 3.046

Review 10.  Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.

Authors:  Ana L Huerta-Alardín; Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2004-10-20       Impact factor: 9.097

View more
  2 in total

Review 1.  Coaxing stem cells for skeletal muscle repair.

Authors:  Karl J A McCullagh; Rita C R Perlingeiro
Journal:  Adv Drug Deliv Rev       Date:  2014-07-15       Impact factor: 15.470

Review 2.  Treatment Opportunities in Patients With Metabolic Myopathies.

Authors:  Mette Cathrine Ørngreen; John Vissing
Journal:  Curr Treat Options Neurol       Date:  2017-09-21       Impact factor: 3.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.